Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMO: Paricalcitol for LVH in CKD
NCT00497146Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2008
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in left ventricular hypertrophy (LVH) comparing Paricalcitol with Placebo (2 arms). Primary endpoint: Change From Baseline in Left Ventricular Mass Index at 48 weeks. Started Feb 2008; status: completed.
02
Drugs
paricalcitol oral solution
03
Conditions
left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT00497146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00497146.